)
RPG Life Sciences (RPGLIFE) investor relations material
RPG Life Sciences Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Integrated pharmaceutical company with domestic and international presence, focusing on branded formulations, generics, and APIs.
Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved by the Board on January 27, 2026.
Business transformation initiatives include building mega brands, expanding global play, and sustainable operations with significant capex infusion.
Strong product portfolio in chronic and specialty therapies, with leadership in immunosuppressants and presence in 50+ markets.
Results reviewed by statutory auditors, with no material misstatements identified.
Financial highlights
Revenue from operations for 9M FY26 grew 4.0% year-over-year to ₹530.6 crore (₹53,063 lakhs).
Q3 FY26 revenue was ₹180.0 crore (₹18,003 lakhs), up 4.2% year-over-year.
EBITDA declined 10.1% year-over-year to ₹127.4 crore, with margin dropping from 27.8% to 24.0%.
PAT (excluding exceptional items) fell 11.3% year-over-year to ₹82.6 crore, with margin at 15.6%.
Net profit for the quarter was ₹2,213 lakhs, compared to ₹3,493 lakhs in the prior year quarter.
Outlook and guidance
Strategic focus on portfolio development, mega-brand building, and expanding API business.
Ongoing digital initiatives and M&A evaluations to drive efficiency and growth.
Continued investment in capacity expansion and talent development.
The transfer of the API division to a wholly owned subsidiary is expected to streamline business structure and improve operational focus, with completion targeted by February 2026.
- TimeTickerHeadlineOpen
- 386
Net profit and revenue fell on lower oil prices and weak margins, despite improved cash flow. - 386
2024 profit fell 16% to RMB48.9B on lower margins, but dividend payout remains robust. - DNLM
Sales and digital growth, margin expansion, and strategic investments drive strong FY25 results. - DNLM
Sales up 3.8% to £1,771m, profit before tax £211m, digital sales 40%, market share 7.9%. - 9412
Profits and equity improved, with upward revisions to full-year forecasts and new subsidiaries added. - NVDA
AI is transforming enterprises by enabling intent-driven innovation and technology-first strategies. - DNLM
H1 sales up 3.6% to £926m; digital mix 41%; PBT to hit lower end of consensus. - CRW
Double-digit growth, strong cash flow, and new leadership drive confidence for FY25. - 7011
Strong revenue and profit growth in FY2025, with raised guidance and key divestiture impact. - 8053
Profit attributable to owners dipped 1.9% despite higher revenues and strong FX gains.
Next RPG Life Sciences earnings date
Next RPG Life Sciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)